Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Reaffirmed as “Outperform” by Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush‘s target price would indicate a potential upside of 118.25% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Stock Down 9.7%

Shares of NASDAQ TLX opened at $10.08 on Wednesday. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The business has a fifty day simple moving average of $11.49 and a two-hundred day simple moving average of $10.78. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $13.11.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TLX. Bank of America Corp DE grew its holdings in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at $120,000. WoodTrust Financial Corp purchased a new stake in shares of Telix Pharmaceuticals during the 3rd quarter valued at $186,000. Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.